EMA accepts GSK’s Blenrep MAA for multiple myeloma for review

22 Jul 2024
www.pharmaceutical-technology.com
EMA accepts GSK’s Blenrep MAA for multiple myeloma for review
Preview
Source: Pharmaceutical Technology
GSK’s ADC is intended for use in combination with bortezomib plus dexamethasone or pomalidomide plus dexamethasone. Credit: HJBC / Shutterstock.
The European Medicines Agency (EMA) has accepted for review GSK’s marketing authorisation application (MAA) for Blenrep (belantamab mafodotin), an antibody-drug conjugate (ADC), to treat relapsed or refractory multiple myeloma (r/r MM).
The ADC is intended for use in combination with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone (PomDex).
The EMA’s Committee for Medicinal Products for Human Use (CHMP) will now commence the formal review process.
The application is supported by interim data from the Phase III DREAMM-7 and DREAMM-8 clinical trials.
The DREAMM-7 trial enrolled 494 participants randomised to receive either the Blenrep combination or comparator drugs.
See Also:Acorda loses Nasdaq listing to cap biotech’s end
EMA accepts GSK’s Blenrep MAA for multiple myeloma for review
Preview
Source: Pharmaceutical Technology
Japan’s FY 2024 pricing reform expected to favour new listed innovative drugs
EMA accepts GSK’s Blenrep MAA for multiple myeloma for review
Preview
Source: Pharmaceutical Technology
302 participants were part of the DREAMM-8 trial. All had prior exposure to lenalidomide, with a substantial proportion refractory to the drug.
The studies showed significant improvements in progression-free survival for Blenrep combinations compared to standard care, meeting primary endpoints.
The DREAMM-7 trial assessed Blenrep plus BorDex against daratumumab plus BorDex while DREAMM-8 trial evaluated Blenrep with PomDex versus bortezomib plus PomDex.
Although a positive trend in overall survival (OS) was observed, it was not statistically significant at the time of the interim analysis, and follow-up for OS is ongoing.
The trials also reported improvements across secondary efficacy endpoints, with the safety profile of the Blenrep combinations aligning with the known profiles of the individual agents.
GSK research and development global head of oncology and senior vice-president Hesham Abdullah stated: “The milestone reinforces the potential for Blenrep to redefine outcomes for patients with multiple myeloma at or after first relapse.
“We are working to bring Blenrep to patients as quickly as possible given the high unmet need and the clinically robust effects of the Blenrep combinations in the DREAMM-7 and DREAMM-8 phase III head-to-head trials.”
The latest development comes after GSK acquired Elsie Biotechnologies for $50m to unlock the potential of oligonucleotide therapeutics.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
[+2]
Indications
Targets
-
Drugs
[+3]
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.